Market Place
Sourcing Support
Sobi`s FDA Acceptance of Avatrombopag NDA for Pediatric ITP
12 Dec 2024 //
GLOBENEWSWIRE
Bulletin from Sobi`s Extraordinary General Meeting (EGM)
11 Dec 2024 //
PR NEWSWIRE
Sobi`s strength in haematology to be showcased at ASH 2024
03 Dec 2024 //
PR NEWSWIRE
Notice of Extraordinary Meeting in Swedish Orphan Biovitrum AB
11 Nov 2024 //
PR NEWSWIRE
Sobi to Present New Immunology Data at ACR Convergence 2024
07 Nov 2024 //
GLOBENEWSWIRE
David Meek is proposed as new Chair of Board of Directors of Sobi
05 Nov 2024 //
PR NEWSWIRE
David Meek Proposed as New Chair of Sobi Board of Directors
04 Nov 2024 //
PR NEWSWIRE
Emapalumab Data in Macrophage Activation Syndrome at ACR
30 Oct 2024 //
PR NEWSWIRE
Invitation: Sobi`s Aspaveli® Phase 3 VALIANT Data Call
25 Oct 2024 //
PR NEWSWIRE
Sobi Reports Strong Growth And Pipeline Momentum In Q3 2024
24 Oct 2024 //
PR NEWSWIRE
Invitation: Sobi`s Q3 2024 report
09 Oct 2024 //
PR NEWSWIRE
New number of shares and votes in Sobi
30 Sep 2024 //
PR NEWSWIRE
Biovitrum`s Biologic Kineret (Anakinra) Receives Suppl Approval in US
19 Sep 2024 //
FDA
Sobi And Enable Injections Partner On Aspaveli® With enFuse® Delivery
12 Sep 2024 //
GLOBENEWSWIRE
Sobi has completed issues of class C shares
29 Aug 2024 //
PR NEWSWIRE
Sobi And Apellis Report Positive Results From Pegcetacoplan Study
09 Aug 2024 //
PR NEWSWIRE
NEJM Publishes ALTUVOCT® Phase 3 Results For Pediatric Hemophilia A
17 Jul 2024 //
PRESS RELEASE
Sobi boosts hematology sales with growth across key brands
16 Jul 2024 //
FIERCE PHARMA
Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
16 Jul 2024 //
PR NEWSWIRE
Sobi Board Exercises Share Repurchase Authorization For Incentive Programmes
15 Jul 2024 //
PR NEWSWIRE
Invitation: Sobi`s Q2 2024 report
03 Jul 2024 //
PR NEWSWIRE
Sobi gets EU okay for long-acting haemophilia A drug
20 Jun 2024 //
PHARMAPHORUM
Pegcetacoplan Noble Phase 2 Positive: Era Late-Breaker Presentation Featured
24 May 2024 //
PR NEWSWIRE
Sobi Emapalumab Fda Fast Track: For Macrophage Activation Syndrome
24 May 2024 //
GLOBENEWSWIRE
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
24 May 2024 //
GLOBENEWSWIRE
Bulletin from Sobi`s Annual General Meeting (AGM)
14 May 2024 //
PR NEWSWIRE
Sobi’s Aspaveli obtains indication extension approval in Europe
09 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Aspaveli Approved In Europe For Treatment Naïve PNH Patients
08 May 2024 //
PR NEWSWIRE
Sobi Completes SEK 3 Billion Senior Bond Issue
08 May 2024 //
PR NEWSWIRE
Sobi Establishes SEK 10B MTN Programme, Base Prospectus
26 Apr 2024 //
PR NEWSWIRE
Sobi®: Positive CHMP Opinion for Efanesoctocog Alfa in Hemophilia A
26 Apr 2024 //
PR NEWSWIRE
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
25 Apr 2024 //
PR NEWSWIRE
Sobi publishes Annual and sustainability report for 2023
02 Apr 2024 //
PR NEWSWIRE
Orexo and Sobi agree to advance feasibility study with AmorphOX
12 Feb 2024 //
PR NEWSWIRE
Invitation: Sobi`s Q4 and FY 2023 report
24 Jan 2024 //
PR NEWSWIRE
Sobi`s Chairman of the Board resigns due to health reasons
05 Jan 2024 //
PR NEWSWIRE
Sobi to present new data at ASH 2023 Annual Meeting
20 Nov 2023 //
PR NEWSWIRE
Health Canada Approves DOPTELET for Two Indications in Thrombocytopenia
06 Nov 2023 //
GLOBENEWSWIRE
Sobi issues series C shares to fulfil its obligations
31 Oct 2023 //
PR NEWSWIRE
Selecta Announces Transition of Clinical Operations of ImmTOR for SEL-212
31 Oct 2023 //
GLOBENEWSWIRE
Sobi publishes Q3 2023 report: Strong revenue and solid performance
30 Oct 2023 //
PR NEWSWIRE
Reminder: Invitation: Sobi`s Q3 2023 report
27 Oct 2023 //
PR NEWSWIRE
Sobi appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer
05 Oct 2023 //
PR NEWSWIRE
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
29 Sep 2023 //
PR NEWSWIRE
Sobi publishes the final outcome of the rights issue
19 Sep 2023 //
PR NEWSWIRE
Sobi publishes the preliminary outcome of the rights issue
18 Sep 2023 //
PR NEWSWIRE
Sobi KOL investor event: Advancing the standard of care in haemophilia
15 Sep 2023 //
PR NEWSWIRE
Sobi KOL investor event: Advancing the standard of care in haemophilia
08 Sep 2023 //
PR NEWSWIRE
Sobi resolves on a rights issue of approximately SEK 6,024 million
22 Aug 2023 //
PR NEWSWIRE
Bulletin from Swedish Orphan Biovitrum (Sobi)`s EGM
15 Aug 2023 //
PR NEWSWIRE
Sobi intends to carry out a rights issue of approximately SEK 6,000 million
18 Jul 2023 //
PR NEWSWIRE
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
18 Jul 2023 //
PR NEWSWIRE
Sobi publishes Q2 2023 report: Growth and pipeline expansion
18 Jul 2023 //
PR NEWSWIRE
Invitation: Sobi`s Q2 2023 report
11 Jul 2023 //
PR NEWSWIRE
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
30 Jun 2023 //
PR NEWSWIRE
Sobi completes acquisition of CTI BioPharma Corp.
26 Jun 2023 //
PR NEWSWIRE
SOBI Late-breaking efanesoctocog alfa data presented at ISTH
25 Jun 2023 //
PR NEWSWIRE
Sobi successfully completes tender offer for all outstanding shares of CTI
24 Jun 2023 //
PR NEWSWIRE
The Board of Directors of Sobi exercises authorisation for repurchase of shares
20 Jun 2023 //
PR NEWSWIRE
Sobi to present new data at the 2023 EHA congress
02 Jun 2023 //
PR NEWSWIRE
